Omics phenotyping in heart failure: the next frontier

Abstract This state-of-the-art review aims to provide an up-to-date look at breakthrough omic technologies that are helping to unravel heart failure (HF) disease mechanisms and heterogeneity. Genomics, transcriptomics, proteomics, and metabolomics in HF are reviewed in depth. In addition, there is a...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2020-09, Vol.41 (36), p.3477-3484
Main Authors: Bayes-Genis, Antoni, Liu, Peter P, Lanfear, David E, de Boer, Rudolf A, González, Arantxa, Thum, Thomas, Emdin, Michele, Januzzi, James L
Format: Article
Language:English
Subjects:
Biomarkers
Genomics
Heart Failure - diagnosis
Heart Failure - genetics
Humans
Metabolomics
Proteomics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract This state-of-the-art review aims to provide an up-to-date look at breakthrough omic technologies that are helping to unravel heart failure (HF) disease mechanisms and heterogeneity. Genomics, transcriptomics, proteomics, and metabolomics in HF are reviewed in depth. In addition, there is a thorough, expert discussion regarding the value of omics in identifying novel disease pathways, advancing understanding of disease mechanisms, differentiating HF phenotypes, yielding biomarkers for diagnosis or prognosis, or identifying new therapeutic targets in HF. The combination of multiple omics technologies may create a more comprehensive picture of the factors and physiology involved in HF than achieved by either one alone and provides a rich resource for predictive phenotype modelling. However, the successful translation of omics tools as solutions to clinical HF requires that the observations are robust and reproducible and can be validated across multiple independent populations to ensure confidence in clinical decision-making.
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehaa270